Suppr超能文献

脱氢表雄酮与生物制剂治疗系统性红斑狼疮

Dehydroepiandrosterone and biologics in the treatment of systemic lupus erythematosus.

作者信息

Furie R

机构信息

Associate Professor of Clinical Medicine, Division of Rheumatology and Allergy-Clinical Immunology, North Shore University Hospital, 300 Community Drive, Manhasset, NY 11030, USA.

出版信息

Curr Rheumatol Rep. 2000 Feb;2(1):44-50. doi: 10.1007/s11926-996-0068-5.

Abstract

Our understanding of the immune system in health and disease has greatly increased over this past decade. An outgrowth of this burgeoning knowledge has been the discovery of novel strategies to treat a variety of autoimmune diseases. As a result, significant advances have been made in the treatment of arthritis with a half-dozen new treatments approved between September, 1998 and November, 1999. Although no new therapies have been approved for the treatment of systemic lupus erythematosus (SLE), this decade has witnessed an unprecedented amount of activity in drug development for this disease. This article specifically addresses the current status of drug development in the area of hormonal and biologic therapies for SLE.

摘要

在过去十年中,我们对免疫系统在健康和疾病状态下的理解有了极大的提升。这一迅速增长的知识所带来的一个成果是,发现了治疗多种自身免疫性疾病的新策略。因此,在1998年9月至1999年11月期间,有六种新疗法获批用于治疗关节炎,在这方面取得了重大进展。虽然目前尚无新疗法获批用于治疗系统性红斑狼疮(SLE),但在这十年间,针对该疾病的药物研发活动达到了前所未有的规模。本文将专门探讨SLE激素和生物疗法领域的药物研发现状。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验